Allegiance Equity Corporation is a Canada-based company engaged in developing treatments for widespread diseases and medical conditions. The Company patents and regulatory approvals and licenses its technologies for royalties and upfront payments. The Company also provides financial and business assistance to emerging corporations in a variety of industries, including the pharmaceutical, medical and biotechnology industries. Its CinG-X product treats and prevents Type 3 resulting from the impact of diabetes on brain function. CinG-X controls glucose metabolism, improve cognitive function, and simultaneously minimize the risk of developing and treating cardiovascular disease, diabetes, dementia and Alzheimerâ€˜s.
|Marilyn Bloovol||President, Chief Executive Officer, Secretary, Director|
|Donald Stott||Chief Financial Officer, Director|
|Melvin Goldberg||Independent Director|